相关实验视频

Updated: Jul 28, 2025

Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells

Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells

Published on: August 12, 2015

生殖系BRCA突变HER2-阴性高级乳腺癌:在使用Talazoparib时克服基因测试和临床考虑方面的挑战

Emily Brugioni¹, Elizabeth Cathcart-Rake², Janie Metsker³

¹Mission Blood + Cancer, Des Moines, IA.

Clinical breast cancer

|May 28, 2023

概括

对BRCA1/2突变的基因测试对于诊断和治疗乳腺癌至关重要,特别是对于那些符合PARP抑制剂治疗条件的患者. 克服测试障碍可以确保最佳的患者护理和治疗选择.

科学领域:

在瘤学瘤学.
医学遗传学医学遗传学
药理学药理学是指药理学的学科.

背景情况:

对BRCA1/2突变的基因测试对于乳腺癌的诊断和管理至关重要.
在BRCA1/2基因突变增加乳腺癌的风险,并表明对PARP抑制剂的潜在敏感性.
经批准的PARP抑制剂 (olaparib,talazoparib) 建议用于生殖系BRCA突变的晚期乳腺癌.

研究的目的:

强调基因检测在乳腺癌护理中的重要性.
讨论患者和临床医生在获得基因检测时所面临的挑战.
通过一个假设的案例研究来说明PARP抑制剂使用的临床考虑.

主要方法:

审查当前的指导方针和临床实践.
介绍了 HER2 阴性转移性乳腺癌与 BRCA 突变的假设案例研究.
讨论talazoparib的治疗开始,剂量,药物相互作用和副作用管理.

主要成果:

根据NCCN的指导方针,建议对所有患有复发性或转移性乳腺癌的患者进行基因检测.
尽管有建议,但许多符合条件的患者没有接受基因检测.
多学科方法和患者参与是治疗转移性乳腺癌的关键.

结论:

基因检测是个性化乳腺癌治疗的基石.
解决对基因测试的访问障碍对于公平护理至关重要.
转移性乳腺癌的有效管理需要仔细考虑针对性疗法,如PARP抑制剂和以患者为中心的决策.

关键词:

生物标志物生物标志物乳腺新生体的形成.社区医学社区医学遗传咨询遗传咨询遗传咨询医学瘤学医学瘤学这是一种PARP抑制剂.

更多相关视频

gDNA Enrichment by a Transposase-based Technology for NGS Analysis of the Whole Sequence of BRCA1, BRCA2, and 9 Genes Involved in DNA Damage Repair

gDNA Enrichment by a Transposase-based Technology for NGS Analysis of the Whole Sequence of BRCA1, BRCA2, and 9 Genes Involved in DNA Damage Repair

Published on: October 6, 2014

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...